Bavarian Nordic A/S
Bavarian Nordic A/S
-0,03 %
176,25 DKK
-0,05
Kurs
176,25
Hög
178,65
Förändring
-0,03 %
Låg
174,50
Uppdaterad
2019-07-19
Öppen
175,85
Factsheet for Bavarian Nordic A/S
Company Profile
Description
Bavarian Nordic is a biotechnology company focused on the development, manufacturing, and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company has a specific focus on diseases for which the unmet medical need is high. Bavarian generates revenue through government research and development and supply contracts, and from its commercial partnerships. The vast majority of the company's revenue is generated in the Netherlands, followed by the United States, Canada, and other geographic markets.
Key Stats
Website: http://www.bavarian-nordic.com
Headquarter country: Denmark
Employees: 426
Market Cap (at close 19-07-2019): DKK 6B
Fiscal Year Ends: december
Stats

Stats 2018 2017 2016 2015 2014
Price/Earnings 909,80 15,60 123,80 60,60
Forward Price/Earnings 6,40 13,30 13,40 263,20
Price/Free Cash Flow 47,80 7,30 163,80 12,80 973,70
Return on Assets -11,60 6,10 1,30 3,10 1,60
Return on Equity -15,40 8,00 1,80 4,60 2,30
Return on Invested Capital -12,10 7,40 1,90 4,60 2,50
Dividend


Dividend/Share:
Ex. Dividend Date:0001-01-01
Trailing Dividend Yield:
Payout Ratio:0,00
Date Currency Amount
Income Statement

Revenue 2018 2017 2016 2015 2014
Total Revenue 500,62 1 370,15 1 006,74 1 020,56 1 216,82
Gross Profit 0,25 1,08 0,71 0,61 0,72
Gross Margin % 49,04% 78,79% 70,42% 59,32% 59,31%
Operating Expenses 2018 2017 2016 2015 2014
EBITDA -300,00 345,00 89,00 124,00 113,00
Net income -362,00 181,00 31,00 59,00 26,00
Basic Earnings Per Share -11,20 5,70 1,00 2,10 1,00
Operating Income -0,35 0,35 0,03 0,00 0,02
Operating Margin % -70,81% 25,78% 3,28% 0,15% 1,37%
Cash Flow

Cash Flow 2018 2017 2016 2015 2014
Operating Cash Flow -289,00 216,00 268,00 105,00 339,00
Capital Expenditures -212,00 -79,00 -92,00 -60,00 -106,00
Free Cash Flow -500,00 137,00 176,00 45,00 233,00
Balance Sheet

Assets 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Current Assets 2 508,26 2 770,49 2 282,57 1 404,26 1 319,12 900,37
Long Term Assets 552,68 382,19 541,13 585,01 568,15 551,84
Total Assets 3 060,94 3 152,67 2 823,70 1 989,26 1 887,27 1 452,21
Liabilities 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Total Current Liabilities 482,70 246,61 751,80 590,23 583,28 389,25
Long Term Liabilities 399,76 54,66 56,55
Total Liabilities 646,37 806,46 646,78
Equity 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Retained Earnings 1 797,12 2 156,88 1 731,90 1 066,56 972,32 652,02
Treasury Stock 0,51 0,23 0,11
Total Stockholder Equity 2 180,63 2 506,30 2 017,24 1 342,48 1 252,09 976,29
Net Tangible Assets 2 148,13 2 473,31 1 934,22 1 234,29 1 142,90 871,66